Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 4:40 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 539206 | NSE: GVBL

Genomic Valley Biotech Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹15.18Overvalued by 43.36%vs CMP ₹26.80

P/E (15.0) × ROE (9.7%) × BV (₹12.80) × DY (2.00%)

Defaults: P/E=15

₹13.18Overvalued by 50.82%vs CMP ₹26.80
MoS: -103.3% (Negative)Confidence: 65/100 (Moderate)Models: All 8: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹14.8121%Over (-44.7%)
Graham NumberEarnings₹18.4316%Over (-31.2%)
Earnings PowerEarnings₹9.6113%Over (-64.1%)
DCFCash Flow₹12.3116%Over (-54.1%)
Net Asset ValueAssets₹12.869%Over (-52%)
EV/EBITDAEnterprise₹14.4311%Over (-46.2%)
Earnings YieldEarnings₹11.809%Over (-56%)
Revenue MultipleRevenue₹4.136%Over (-84.6%)
Consensus (8 models)₹13.18100%Overvalued
Key Drivers: Wide model spread (₹4–₹18) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -2.4% · Defaults: P/E=15

*Investments are subject to market risks

Investment Snapshot

45
Genomic Valley Biotech Ltd scores 45/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health49/100 · Moderate
ROCE 11.8% AverageROE 9.7% AverageD/E 0.34 ModerateInterest Coverage 0.0x RiskyProfitable 3/5 years Mixed
Smart Money50/100 · Moderate
Promoter holding at 46.1% Stable
Earnings Quality55/100 · Moderate
OPM expanding (-255% → 32%) ImprovingWorking capital: 917 days Capital intensive
Quarterly Momentum15/100 · Weak
Revenue (4Q): -17% YoY DecliningProfit (4Q): -113% YoY DecliningOPM: 20.0% (down 52.7% YoY) Margin pressure
Industry Rank60/100 · Moderate
ROCE 11.8% vs industry 17.0% Average3Y sales CAGR: 129% High growth

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Genomic Valley Biotech Ltd Investor Signals

Computed from valuation, cash flow, balance sheet, ownership and quarterly trend data already available in this stock page.

Value Trap Score
20/100
Low
Derived from: Cheapness + weak quality + weak cash support
Current data: P/E 0.0 vs Ind 15.2 | ROCE 11.8% | ROE 9.7% | CFO/NP N/A
Balance Sheet Stress
20/100
Comfortable
Derived from: Leverage + debt servicing + liquidity + debt trend
Current data: D/E 0.34x | IntCov 0.0x | Current 0.18x | Borrow/Reserve 0.00x
Cash Flow Reliability
43/100
Mixed
Derived from: Cash backing of earnings + working capital pressure
Current data: CFO ₹0 Cr | NP ₹0 Cr | CFO/NP N/A
Ownership Accumulation
-50
Distribution
Derived from: FII + DII + promoter direction, adjusted by crowding
Current data: FII N/A | DII N/A | Prom -0.66 pp
Business Momentum
+36
Stable
Derived from: Latest quarter sales + profit + OPM change
Current data: Q Sales -44.4% | Q NP N/A | Q OPM +20.0 pp
Derived FieldValueHow it is derived
Valuation Gap %-50.8%((Fair Value - CMP) / CMP) × 100
Borrowings / Reserves0.00xLatest borrowings divided by latest reserves
CFO / Net ProfitN/ALatest operating cash flow divided by latest net profit
FII ChangeN/ALatest FII% minus previous FII%
DII ChangeN/ALatest DII% minus previous DII%
Promoter Change-0.66 ppLatest promoter% minus previous promoter%
Shareholder Count Change+63Latest shareholder count minus previous count
Quarterly Sales Change-44.4%Latest quarter sales vs previous quarter sales
Quarterly Profit ChangeN/ALatest quarter net profit vs previous quarter net profit
Quarterly OPM Change+20.0 ppLatest quarter OPM minus previous quarter OPM

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 4:40 am

Market Cap 8.17 Cr.
Current Price 26.8
Intrinsic Value₹13.18
High / Low 64.0/20.1
Stock P/E
Book Value 12.8
Dividend Yield0.00 %
ROCE11.8 %
ROE9.69 %
Face Value 10.0
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Genomic Valley Biotech Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Genomic Valley Biotech Ltd 8.17 Cr. 26.8 64.0/20.1 12.80.00 %11.8 %9.69 % 10.0
Genesis IBRC India Ltd 448 Cr. 99.0 185/18.3 6.420.00 %51.6 %51.6 % 10.0
Shreeoswal Seeds & Chemicals Ltd 95.0 Cr. 10.4 20.3/9.6716.8 5.230.00 %9.88 %8.41 % 2.00
Nath Bio-Genes (India) Ltd 261 Cr. 137 239/1265.29 3621.45 %7.35 %6.77 % 10.0
Continental Seeds and Chemicals Ltd 18.2 Cr. 13.0 32.0/13.023.6 22.50.00 %4.24 %2.87 % 10.0
Industry Average354.50 Cr57.2415.2381.790.29%16.97%15.87%8.40

All Competitor Stocks of Genomic Valley Biotech Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 0.671.000.060.070.040.000.160.210.220.260.090.090.05
Expenses 0.630.070.030.050.020.040.030.070.060.260.060.090.04
Operating Profit 0.040.930.030.020.02-0.040.130.140.160.000.030.000.01
OPM % 5.97%93.00%50.00%28.57%50.00%81.25%66.67%72.73%0.00%33.33%0.00%20.00%
Other Income -0.890.040.000.000.000.000.000.010.000.000.000.000.00
Interest 0.000.000.000.000.000.000.000.000.000.000.000.000.00
Depreciation 0.00-0.010.000.000.000.000.000.000.000.000.000.000.00
Profit before tax -0.850.980.030.020.02-0.040.130.150.160.000.030.000.01
Tax % 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Net Profit -0.850.980.030.020.02-0.040.130.150.16-0.080.020.000.01
EPS in Rs -2.783.210.100.070.07-0.130.430.490.52-0.260.070.000.03

Last Updated: February 1, 2026, 8:16 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 27, 2026, 5:46 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 0.090.030.110.440.590.990.850.210.072.720.170.840.49
Expenses 0.080.070.540.480.490.570.300.340.451.840.150.400.45
Operating Profit 0.01-0.04-0.43-0.040.100.420.55-0.13-0.380.880.020.440.04
OPM % 11.11%-133.33%-390.91%-9.09%16.95%42.42%64.71%-61.90%-542.86%32.35%11.76%52.38%8.16%
Other Income 0.010.070.160.010.030.010.010.000.50-0.220.000.000.00
Interest 0.010.030.020.000.000.000.180.180.040.000.000.000.00
Depreciation 0.000.010.050.040.080.190.180.190.080.010.000.000.00
Profit before tax 0.01-0.01-0.34-0.070.050.240.20-0.500.000.650.020.440.04
Tax % 0.00%0.00%-2.94%0.00%40.00%0.00%-40.00%12.00%0.00%0.00%20.45%
Net Profit 0.00-0.01-0.33-0.070.030.230.29-0.56-0.010.650.020.36-0.05
EPS in Rs 0.00-0.03-1.08-0.230.100.750.95-1.83-0.032.130.071.18-0.16
Dividend Payout % 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-3200.00%78.79%142.86%666.67%26.09%-293.10%98.21%6600.00%-96.92%1700.00%
Change in YoY Net Profit Growth (%)0.00%3278.79%64.07%523.81%-640.58%-319.19%391.32%6501.79%-6696.92%1796.92%

Genomic Valley Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:40%
5 Years:0%
3 Years:129%
TTM:189%
Compounded Profit Growth
10 Years:44%
5 Years:4%
3 Years:42%
TTM:92%
Stock Price CAGR
10 Years:%
5 Years:18%
3 Years:%
1 Year:-42%
Return on Equity
10 Years:1%
5 Years:2%
3 Years:12%
Last Year:10%

Last Updated: September 5, 2025, 3:36 pm

Balance Sheet

Last Updated: February 1, 2026, 2:52 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 3.053.053.053.053.053.053.053.053.053.053.053.053.05
Reserves 1.851.841.511.441.471.711.991.43-0.180.470.490.840.87
Borrowings 0.750.750.750.750.751.481.481.550.000.000.000.000.00
Other Liabilities 0.610.800.730.781.410.941.491.590.920.900.790.470.41
Total Liabilities 6.266.446.046.026.687.188.017.623.794.424.334.364.33
Fixed Assets 3.023.153.183.634.124.314.475.861.750.000.000.010.01
CWIP 0.000.000.000.000.380.490.490.490.000.000.000.000.00
Investments 0.000.550.110.000.000.000.000.000.000.000.020.000.00
Other Assets 3.242.742.752.392.182.383.051.272.044.424.314.354.32
Total Assets 6.266.446.046.026.687.188.017.623.794.424.334.364.33

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 0.000.09-0.690.350.87-1.040.441.48-2.13-0.78-0.020.03
Cash from Investing Activity + 0.01-0.650.53-0.31-0.910.37-0.47-1.583.671.52-0.020.01
Cash from Financing Activity + 0.000.000.000.000.000.730.000.07-1.55-0.700.000.00
Net Cash Flow 0.01-0.56-0.160.04-0.040.06-0.04-0.03-0.010.04-0.040.04
Free Cash Flow 0.00-0.05-0.77-0.15-0.07-0.68-0.04-0.103.220.70-0.020.02
CFO/OP 0%-225%160%-875%870%-248%80%-1,138%561%-89%-100%27%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-0.74-0.79-1.18-0.79-0.65-1.06-0.93-1.68-0.380.880.020.44

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 0.000.000.000.0012.3722.1242.94104.290.00297.905,432.06960.30
Inventory Days 0.000.000.000.000.00486.67
Days Payable 17.38
Cash Conversion Cycle 0.000.000.000.0012.3722.1242.94104.290.00297.905,432.061,429.58
Working Capital Days 7,746.11-8,881.67-1,659.09-514.32-804.2455.30-176.06-1,251.434,849.29221.424,530.29916.85
ROCE %0.41%0.35%-5.84%-0.57%0.57%4.17%5.96%-5.10%-8.54%28.48%0.57%11.83%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 67.18%67.18%66.32%65.04%64.20%64.14%54.67%46.83%46.78%46.72%46.72%46.06%
Public 32.82%32.82%33.68%34.96%35.80%35.86%45.33%53.16%53.20%53.28%53.29%53.94%
No. of Shareholders 3803815911,0141,3341,5402,1282,4972,5042,4602,4592,522

Shareholding Pattern Chart

No. of Shareholders

Genomic Valley Biotech Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 1.170.052.12-0.03-1.83
Diluted EPS (Rs.) 1.170.052.12-0.03-1.83
Cash EPS (Rs.) 1.170.052.150.24-1.21
Book Value[Excl.RevalReserv]/Share (Rs.) 12.7611.6011.559.4214.69
Book Value[Incl.RevalReserv]/Share (Rs.) 12.7611.6011.559.4214.69
Revenue From Operations / Share (Rs.) 2.760.548.910.230.68
PBDIT / Share (Rs.) 1.450.053.02-0.96-0.44
PBIT / Share (Rs.) 1.450.042.99-1.24-1.06
PBT / Share (Rs.) 1.450.042.12-1.38-1.64
Net Profit / Share (Rs.) 1.170.042.12-0.03-1.83
PBDIT Margin (%) 52.609.8333.83-416.43-64.94
PBIT Margin (%) 52.309.1733.54-535.97-155.88
PBT Margin (%) 52.309.1723.83-596.37-241.16
Net Profit Margin (%) 42.199.1923.81-13.23-268.67
Return on Networth / Equity (%) 9.130.4218.38-0.32-12.45
Return on Capital Employeed (%) 11.320.4225.89-10.55-4.80
Return On Assets (%) 8.170.3514.66-0.24-7.33
Long Term Debt / Equity (X) 0.000.000.000.000.34
Total Debt / Equity (X) 0.000.160.170.000.34
Asset Turnover Ratio (%) 0.190.030.660.010.02
Current Ratio (X) 5.733.682.885.310.18
Quick Ratio (X) 5.103.682.885.310.18
Inventory Turnover Ratio (X) 0.000.000.000.000.08
Interest Coverage Ratio (X) 0.000.000.00-6.89-0.76
Interest Coverage Ratio (Post Tax) (X) 0.000.000.00-9.05-2.15
Enterprise Value (Cr.) 17.8511.207.217.568.74
EV / Net Operating Revenue (X) 21.1567.842.65107.1042.02
EV / EBITDA (X) 40.21689.517.83-25.72-64.70
MarketCap / Net Operating Revenue (X) 21.2164.232.44107.1434.64
Price / BV (X) 4.592.991.882.631.61
Price / Net Operating Revenue (X) 21.2164.282.44107.1434.65
EarningsYield 0.010.000.090.00-0.07

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Genomic Valley Biotech Ltd. is a Public Limited Listed company incorporated on 15/03/1996 and has its registered office in the State of Haryana, India. Company's Corporate Identification Number(CIN) is L01122HR1994PLC033029 and registration number is 033029. Currently Company is involved in the business activities of Growing of cucumbers, gherkins, aubergines, tomatoes, watermelons, cantaloupes , melons and other fruit-bearing vegetables. Company's Total Operating Revenue is Rs. 0.84 Cr. and Equity Capital is Rs. 3.05 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Seeds/Tissue Culture/Bio Technology4KM Stone, Berry Charra Road, Vill. Kherka, Musalman, P.O. Tandah Tehsil - Bahadurgarh, Jhajjar District Haryana 124507Contact not found
Management
NamePosition Held
Mr. Yogesh AgrawalManaging Director
Mrs. Parul AgrawalNon Executive Director
Mr. Ashok KumarNon Exe.Non Ind.Director
Mr. Satendra Kumar GoyalInd. Non-Executive Director

FAQ

What is the intrinsic value of Genomic Valley Biotech Ltd and is it undervalued?

As of 05 April 2026, Genomic Valley Biotech Ltd's intrinsic value is ₹13.18, which is 50.82% lower than the current market price of ₹26.80, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (9.69 %), book value (₹12.8), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd is trading at ₹26.80 as of 05 April 2026, with a FY2026-2027 high of ₹64.0 and low of ₹20.1. The stock is currently near its 52-week low. Market cap stands at ₹8.17 Cr..

How does Genomic Valley Biotech Ltd's P/E ratio compare to its industry?

Genomic Valley Biotech Ltd has a P/E ratio of , which is below the industry average of 15.23. This is broadly in line with or below the industry average.

Is Genomic Valley Biotech Ltd financially healthy?

Key indicators for Genomic Valley Biotech Ltd: ROCE of 11.8 % is moderate. Dividend yield is 0.00 %.

Is Genomic Valley Biotech Ltd profitable and how is the profit trend?

Genomic Valley Biotech Ltd reported a net profit of ₹0 Cr in Mar 2025 on revenue of ₹1 Cr. Compared to ₹0 Cr in Mar 2022, the net profit shows an improving trend.

Does Genomic Valley Biotech Ltd pay dividends?

Genomic Valley Biotech Ltd has a dividend yield of 0.00 % at the current price of ₹26.80. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Genomic Valley Biotech Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports